Aaron Logan, MD, PhD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, describes strategies to optimize transplant with data from ongoing trials. Dr Logan discusses the use of blinatumomab, a bispecific T-cell engager (BiTE) antibody, to achieve measurable residual disease (MRD) negativity prior to transplant to further reduce the likelihood of relapse after transplantation and increase survival benefit. Dr Logan further talks on functional status prior to transplant to better predict outcomes of transplant. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

свернуть